Phase III multicenter, open label study of brigatinib (AP26113) vs. crizotinib in patients with advanced ALK-positive lung cancer. Protocol: AP26113-13-301
Ramdomized, phase III clinic trial in paralel groups of OSE 2101 in second line following failure of platinum-based chemotherapy, or as third line following failure of platinum and immune control point inhibitors, compared with standard treatment (docetaxel or pemetrexed) in patients with HLA-A2 positive and metastatic or locally-advanced non-small cell lung cancer (IIIB) not eligible for radiotherapy. Protocol OSE2101C301
Phase IIa clinical trial of safety and efficacy of AZD9291 in treatment-naïve patients with EGFR mutated advanced non-small-cell lung cancer (NSCLC) with concommitant presence of the EGFR T790M mutation. Protocol: MedOPP112
A multicenter, international, rollover study of alectinib in patients with anaplastic lymphoma kinase (ALK)-positive or rearranged during transfection (RET)-positive cancer.
A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, stage IV biomarker positive, wild type EGF-R NSCLC patients eligible toreceive standard treatment and supportive care. Protocol: BV-NSCLC-002
A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer. Protocol: 54767414LUC2001
A multi-country retrospective chart review study of patients with ALK-positive, BRAF V600-positive, and cMET-positive (ABC) non-small cell lung cancer (NSCLC).
Phase I/II study of oral S49076 in combination with gefitinib in advanced non-small-cell lung cancer patients with EGFR mutations who have progressed following treatment on EGFR tyrosine kinase inhibitor. Protocol: CL1-49076-003
A phase ib study evaluating cobimetinib plus atezolizumab in patients with advanced brafv600 wild-type melanoma who have progressed during or after treatment with anti−pd-1 therapy.